PL377611A1 - Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi - Google Patents
Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymiInfo
- Publication number
- PL377611A1 PL377611A1 PL377611A PL37761103A PL377611A1 PL 377611 A1 PL377611 A1 PL 377611A1 PL 377611 A PL377611 A PL 377611A PL 37761103 A PL37761103 A PL 37761103A PL 377611 A1 PL377611 A1 PL 377611A1
- Authority
- PL
- Poland
- Prior art keywords
- agents
- combination
- beta receptor
- lymphotoxin beta
- chemotherapeutic agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43518502P | 2002-12-20 | 2002-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL377611A1 true PL377611A1 (pl) | 2006-02-06 |
Family
ID=32682180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL377611A PL377611A1 (pl) | 2002-12-20 | 2003-12-22 | Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi |
Country Status (16)
Country | Link |
---|---|
US (1) | US20060134102A1 (pl) |
EP (1) | EP1585547A4 (pl) |
JP (1) | JP2006513225A (pl) |
KR (1) | KR20050094819A (pl) |
CN (1) | CN1753692A (pl) |
AU (1) | AU2003303339A1 (pl) |
BR (1) | BR0317573A (pl) |
CA (1) | CA2509495A1 (pl) |
EA (1) | EA200501019A1 (pl) |
IS (1) | IS7900A (pl) |
MX (1) | MXPA05006663A (pl) |
NO (1) | NO20053529L (pl) |
PL (1) | PL377611A1 (pl) |
RS (1) | RS20050481A (pl) |
WO (1) | WO2004058183A2 (pl) |
ZA (1) | ZA200505543B (pl) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
GEP20063752B (en) * | 2000-10-13 | 2006-02-27 | Biogen Inc | Humanized Anti-LT-Beta-R Antibodies |
CA2490280A1 (en) * | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
NZ537965A (en) * | 2002-07-01 | 2008-04-30 | Biogen Idec Inc | Humanized anti-lymphotoxin beta receptor antibodies |
WO2004058191A2 (en) * | 2002-12-20 | 2004-07-15 | Biogen Idec Ma Inc. | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
EP1641827A2 (en) * | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
CA2560742A1 (en) * | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
ES2432091T5 (es) | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
WO2006125632A2 (en) * | 2005-05-24 | 2006-11-30 | Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh | Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy |
AU2007258189A1 (en) * | 2006-06-15 | 2007-12-21 | Biogen Idec Ma Inc. | Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents |
CL2007002926A1 (es) | 2006-10-12 | 2008-05-16 | Genentech Inc | Anticuerpo antilinfotoxina alfa (lt-alfa); composicion con el anticuerpo; hibridoma pta-7538; acido nucleico codificante del anticuerpo; vector y celula huesped que comprenden el acido nucleico; metodo para inhibir la proliferacion celular activada p |
CA2666934A1 (en) * | 2006-10-20 | 2008-04-24 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
US8338376B2 (en) * | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
WO2017062604A1 (en) | 2015-10-06 | 2017-04-13 | Regents Of The University Of Minnesota | Therapeutic compounds and methods |
JOP20190100A1 (ar) | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها |
EP3807401A1 (en) * | 2018-06-15 | 2021-04-21 | Universität Bern | LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES |
KR102232659B1 (ko) * | 2018-07-16 | 2021-03-26 | 전북대학교 산학협력단 | 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도 |
CN115087670A (zh) * | 2019-12-11 | 2022-09-20 | 西拉格国际有限责任公司 | 包含ltbr和edb结合结构域的多特异性结合分子及其用途 |
CN117327174A (zh) * | 2022-06-24 | 2024-01-02 | 广东菲鹏制药股份有限公司 | 抗新型冠状病毒人源化多价结合蛋白及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
AU725351B2 (en) * | 1995-01-26 | 2000-10-12 | Biogen Idec Ma Inc. | Lymphotoxin-alpha/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents |
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
EE05213B1 (et) * | 1996-10-25 | 2009-10-15 | Biogen, Incorporated | Lmfotoksiin- β retseptori (LT- β-R) blokeeriva agensi kasutamine ja LT- β-R-i blokeerivat agensit ning CD40L-i blokeerivat agensit sisaldav farmatseutiline kompositsioon |
US7060667B1 (en) * | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
GEP20063752B (en) * | 2000-10-13 | 2006-02-27 | Biogen Inc | Humanized Anti-LT-Beta-R Antibodies |
US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
NZ537965A (en) * | 2002-07-01 | 2008-04-30 | Biogen Idec Inc | Humanized anti-lymphotoxin beta receptor antibodies |
WO2004058191A2 (en) * | 2002-12-20 | 2004-07-15 | Biogen Idec Ma Inc. | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
CA2560742A1 (en) * | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
-
2003
- 2003-12-22 CN CNA2003801099160A patent/CN1753692A/zh active Pending
- 2003-12-22 WO PCT/US2003/041243 patent/WO2004058183A2/en active Application Filing
- 2003-12-22 RS YUP-2005/0481A patent/RS20050481A/sr unknown
- 2003-12-22 EA EA200501019A patent/EA200501019A1/ru unknown
- 2003-12-22 CA CA002509495A patent/CA2509495A1/en not_active Abandoned
- 2003-12-22 BR BR0317573-1A patent/BR0317573A/pt not_active IP Right Cessation
- 2003-12-22 KR KR1020057011596A patent/KR20050094819A/ko not_active Application Discontinuation
- 2003-12-22 MX MXPA05006663A patent/MXPA05006663A/es not_active Application Discontinuation
- 2003-12-22 JP JP2004564044A patent/JP2006513225A/ja active Pending
- 2003-12-22 AU AU2003303339A patent/AU2003303339A1/en not_active Abandoned
- 2003-12-22 EP EP03808561A patent/EP1585547A4/en not_active Withdrawn
- 2003-12-22 PL PL377611A patent/PL377611A1/pl unknown
-
2005
- 2005-06-17 US US11/156,109 patent/US20060134102A1/en not_active Abandoned
- 2005-06-20 IS IS7900A patent/IS7900A/is unknown
- 2005-07-08 ZA ZA200505543A patent/ZA200505543B/xx unknown
- 2005-07-19 NO NO20053529A patent/NO20053529L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2006513225A (ja) | 2006-04-20 |
CN1753692A (zh) | 2006-03-29 |
RS20050481A (en) | 2007-08-03 |
KR20050094819A (ko) | 2005-09-28 |
NO20053529L (no) | 2005-09-20 |
EA200501019A1 (ru) | 2006-06-30 |
IS7900A (is) | 2005-06-20 |
ZA200505543B (en) | 2006-12-27 |
EP1585547A4 (en) | 2006-10-25 |
WO2004058183A3 (en) | 2004-12-09 |
EP1585547A2 (en) | 2005-10-19 |
BR0317573A (pt) | 2005-11-22 |
MXPA05006663A (es) | 2005-09-30 |
NO20053529D0 (no) | 2005-07-19 |
AU2003303339A1 (en) | 2004-07-22 |
CA2509495A1 (en) | 2004-07-15 |
WO2004058183A2 (en) | 2004-07-15 |
US20060134102A1 (en) | 2006-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200505543B (en) | Lymphotoxin beta receptor agents in combination with chemotherapeutic agents | |
HK1078095A1 (en) | Corticotropin releasing factor receptor 2 agonists | |
GB2400312B (en) | Back support structure | |
AU2003275135A8 (en) | Pouch with spout | |
GB0401363D0 (en) | Hinge unit and hinge structure using the same | |
EP1552981A4 (en) | SEAT STRUCTURE | |
IL173746A0 (en) | Modified il-4 mutein receptor antagonists | |
GB2396016B (en) | J-spectroscopy in the wellbore | |
PL368410A1 (pl) | Kompozycja poliolefinowa o ulepszonej odporności na ścieranie | |
AU2003275436A8 (en) | Recliner mechanism | |
PL370221A1 (pl) | 2-Oksazoloaminy oraz zastosowanie ich jako antagonistów receptora 5-HT2B | |
GB2388905B (en) | Improvements in flow metering | |
EP1501722A4 (en) | IMPROVEMENTS IN THE BEAUPRES | |
GB0214954D0 (en) | Improvements in feeding mechanisms | |
ZA200404994B (en) | Corticotropin releasing factor 2 receptor agonists | |
SI1465923T1 (sl) | Agonisti receptorja 2 faktorja sproščanja kortikotropina | |
GB0209507D0 (en) | Nuclear receptor structure | |
AU2003242849A8 (en) | Nuclear hormone receptor | |
GB0211204D0 (en) | Receptor and its ligand | |
TW515457U (en) | Fixing seat used in drainpipe | |
GB0418191D0 (en) | J-spectroscopy in the wellbore | |
GB0211205D0 (en) | Receptor and ligand | |
TW515247U (en) | Zipper with dual rails | |
AU2003285989A1 (en) | Mutations in gaba-b receptor 1 associated with epilepsy | |
TW553219U (en) | Mat with magnetization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |